Skip to main navigation Skip to search Skip to main content

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry